US2011077207A1PendingUtilityA1

Method for treating inflammation

Assignee: ZYMOGENETICS INCPriority: Sep 15, 2000Filed: Nov 9, 2010Published: Mar 31, 2011

Est. expirySep 15, 2020(expired)· nominal 20-yr term from priority

Inventors:Yasmin A. Chandrasekher Stephen R. Jaspers

A61P 37/00A61P 29/00A61K 38/1793C07K 14/7155C07K 2319/30

PatentIndex Score

Cited by

References

Claims

Abstract

A method for treating down-regulating IL-19 or mda7 by administering the soluble IL-20RA/IL-20R heterodimeric receptor.

Claims

exact text as granted — not AI-modified

1 . A method down-regulating IL-19 comprising administering to an individual a soluble heterodimeric receptor comprising the extracellular domain of IL-20RA and the extracellular domain of IL-20RB. 
     
     
         2 . The method of  claim 1 , wherein the extracellular domain of IL-20RA comprises SEQ ID NO:3 and the extracellular domain of IL-20RB comprises SEQ ID NO:6. 
     
     
         3 . The method of  claim 1  or  2 , wherein the extracellular domain of IL-20RA is fused at its carboxy terminus to a constant region of an immunoglobulin heavy chain, and the extracellular domain of IL20RB is fused at its carboxy terminus to a constant region of an immunoglobulin light chain, such that a disulfide bond is formed between the heavy and light chains to form the soluble heterodimeric receptor. 
     
     
         4 . The method of  claim 1  or  2 , wherein the extracellular domain of IL-20RB is fused at its carboxy terminus to a constant region of an immunoglobulin heavy chain, and the extracellular domain of IL20RA is fused at its carboxy terminus to a constant region of an immunoglobulin light chain, such that a disulfide bond is formed between the heavy and light chains to form the soluble heterodimeric receptor.

Join the waitlist — get patent alerts

Track US2011077207A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.